Search Results

ExoPTEN Preclinical Study Demonstrates Significant Potential for Enhancing Motor Function, Blood Flow, and Spinal Cord Injury Recovery ExoPTEN’s Preclinical Study Demonstrates Significant for Enhancing Motor Function, Increasing Blood Flow, and Faster Recovery After Spinal Cord Injuries

NurExone Biologic to Present at MIXiii 2025; Professor Michael Belkin, Head of NurExone Ophthalmology Project, to Receive Lifetime Achievement Award TORONTO and HAIFA, Israel, Feb. 27, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”) is pleased to announce that it has been...

NurExone Biologic Recognized as a 2025 TSX Venture 50™ Top Performing Stock TORONTO and HAIFA, Israel, Feb. 19, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”) is proud to announce its inclusion in the 2025...

NurExone Biologic Continues Expansion of U.S. Presence and Awareness with Prestigious Conference Presentation TORONTO and HAIFA, Israel, Feb. 14, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (Germany: J90) (“NurExone” or the “Company”) is excited to announce that it will be...

NurExone Biologic Secures Master Cell Bank NurExone Biologic Secures Master Cell Bank - a Key Milestone for Therapeutic Exosome Production